BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple Myeloma
Bristol Myers Squibb's Zenbexus becomes the first CELMoD and the first multiple-myeloma drug approved on a minimal-residual-disease endpoint, landing the same day regulators on both sides of the Atlantic escalated data-integrity and confirmatory-evidence enforcement against already-marketed products.
pharminent
August 14, 2026 (Last updated: August 14, 2026)
STRATEGIC NEWS WATCH — August 14, 2026
Bristol Myers Squibb’s Zenbexus becomes the first CELMoD and the first multiple-myeloma drug approved on a minimal-residual-disease endpoint, landing the same day regulators on both sides of the Atlantic escalated data-integrity and confirmatory-evidence enforcement against already-marketed products.
Today’s top developments:
Bristol Myers Squibb won accelerated FDA approval for Zenbexus (iberdomide) — the first cleared CELMoD, or cereblon E3 ligase modulator degrader, and the first multiple-myeloma approval built on minimal residual disease as a surrogate endpoint — validating years of targeted protein-degradation investment and signaling MRD’s arrival as an accelerated-approval pathway in hematologic cancers (Fierce Pharma)
European regulators revoked the marketing authorization for Amgen’s Tavneos (avacopan), citing “serious breaches” after finding that ChemoCentryx personnel — from the biotech Amgen bought for $3.7 billion in 2022 — viewed unblinded data after database lock and re-adjudicated nine patients to flip a non-significant week-52 result into a positive one; the EMA called the application data “incorrect and misleading” even as Tavneos sales grew 36% to $150 million in Q2 (BioSpace)
The FDA raised “substantial concerns regarding the benefit-risk” of ADC Therapeutics’ confirmatory Phase 3 LOTIS-5 trial for Zynlonta (loncastuximab tesirine) in diffuse large B-cell lymphoma, where 13.2% of treated patients died versus 4.6% on control against only a 27% progression-free-survival gain and no overall-survival benefit — sending shares down more than 13% and putting the drug’s accelerated approval at risk (Pharmaphorum)
Capricor Therapeutics shares surged after the FDA agreed to review new data for deramiocel, its cell therapy for Duchenne muscular dystrophy cardiomyopathy, ahead of an August 22, 2026 PDUFA date — a last-minute reprieve that follows an FDA advisory committee’s 9-3 vote against the drug’s effectiveness and a briefing document challenging the pivotal HOPE-3 trial (Reuters)
U.S. most-favored-nation pricing is already curbing medicines access in Switzerland, with trade body Interpharma reporting that members declined to submit 7 of 22 new innovative drugs for reimbursement between January 2025 and June 2026 — and skipped a Swissmedic filing entirely in three cases — to avoid setting low reference prices that would drag down U.S. pricing, warning of a “two-tiered healthcare system” (Pharmaphorum)
What to Watch
MRD as regulatory currency — Zenbexus’s clearance on a minimal-residual-disease endpoint could push sponsors of competing myeloma programs to redesign pivotal trials around MRD thresholds, compressing timelines but inviting fresh FDA scrutiny of how well the surrogate tracks long-term survival.
Data-integrity enforcement wave — The EU’s Tavneos revocation and the FDA’s LOTIS-5 concerns land in the same week, signaling tougher enforcement on the confirmatory evidence and trial conduct underpinning accelerated approvals; watch whether more marketed products face withdrawal pressure on integrity grounds.
MFN spillover into Europe — With roughly a third of new medicines being withheld from Swiss reimbursement to protect U.S. reference pricing, watch for widening launch delays across other low-priced reference markets and whether European payers or policymakers respond.
Capricor’s August 22 binary — The FDA’s willingness to review new deramiocel data sets up an imminent make-or-break PDUFA decision that must reconcile a 9-3 advisory-committee vote against effectiveness with the agency’s late-stage openness; the outcome will shape expectations for distressed cell-therapy programs.
Immunology financing and the externalization pivot — Khartis’s $95 million stealth debut and BioCryst’s shift toward externally sourced assets both point to where capital is flowing — credentialed immunology platforms and late-stage in-licensing over internal discovery; watch whether mid-caps keep trading research spend for business development as the model spreads.
